Navigation Links
ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test

REYKJAVIK, Iceland, and SALT LAKE CITY, Utah, July 20, 2010 /PRNewswire/ --

- U.S. Laboratories and Physicians Will be Able to use Their ARUP Accounts to Order deCODE's Test for Assessing Risk of Prostate Cancer

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

Under the terms of the non-exclusive agreement, ARUP will integrate deCODE ProstateCancer(TM) into the portfolio of tests it offers to leading academic medical centers, public and private healthcare providers, and major hospitals across the United States. ARUP's clients will order the test, submit samples and receive results through ARUP, with deCODE conducting the genetic analysis in its CAP and CLIA-certified laboratory.

deCODE ProstateCancer measures 25 common single-letter variations, or SNPs, in the sequence of the human genome that are associated with the risk of prostate cancer. These SNPs were validated in tens of thousands of patients and controls in many populations. The risk conferred by these common SNPs is independent of family history, and does not correlate with benign prostatic hyperplasia (a non-cancerous enlargement of the prostate). The test can identify approximately 15% of men in the general population who are at double the average risk of prostate cancer as well as 5% who have triple the average risk. This test is complementary to standard clinical risk screening, including PSA, providing additional information for a more complete and personalized picture of individual risk to help doctors manage effective screening and early-detection strategies.

"The management of patients with elevated or borderline PSA continues to be a challenge, and having the additional knowledge of a patient's genetic risk for prostate cancer can be very useful. We are pleased to be working with deCODE, who has developed this test through a number of large clinical studies and continues to demonstrate excellent scientific productivity in the area of human genetics," said Edward Ashwood, MD, President and CEO of ARUP Laboratories.

"We are excited to be partnering with ARUP to increase the availability of our prostate cancer test to physicians and their patients. The quality and breadth of their services, and their range of customers across the healthcare spectrum, make them an excellent partner. Our test helps to meet the need for improved risk stratification and patient outcomes, and we believe that this alliance will make these benefits available to a greater number of patients," said Kari Stefansson, Executive Chairman and President of Research at deCODE.

ARUP Laboratories plans to begin offering deCODE's prostate cancer risk test (ARUP test code 2003326) to clients in the fall of 2010.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests, intellectual property and analytical tools to partners, and provides comprehensive genotyping, sequencing and data analysis services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Visit us on the web at; at; at; and on our blog at

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and an enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 2,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology(R). For more information please visit

Media Contacts

Edward Farmer, deCODE, +44(0)7796-010107, or

Gisli Arnason, deCODE, +354-570-1825,

Kristofer Beldin, ARUP Laboratories, +1(801)583-2787, ext. 2451 (wk)/ +1(801)870-4064 (cell) or

Cyndee Holden, ARUP Laboratories, (801)583-2787, ext. 3318 (wk)/ +1(801)386-6637 (cell)

SOURCE DeCODE Genetics Inc & ARUP Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AIT Laboratories Expands Pharma Services
2. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
3. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
4. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
5. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
6. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
7. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
9. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
10. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
11. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):